Deborah Marsden1. 1. Division of Genetics and Metabolism, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.
Abstract
PURPOSE: To review the narratives that detailed the most important features of Infantile Onset Pompe disease (IOPD) from the physician's perspective, submitted as part of a large multicenter, multinational epidemiologic natural history study. METHODS: Inclusion in the epidemiologic study required documentation of onset of symptoms in the first 12 months of age and GAA enzyme deficiency or GAA mutation(s). In all, 300 cases were screened; 168 cases from 33 study sites in 9 countries met all eligibility criteria. In addition, 125 narratives that summarized the most important clinical features of IOPD, reflecting the opinion of the participating physicians who had provided access to the records for the independent review, were analyzed and are reported separately. A total of 98 variables were analyzed. RESULTS: Hypotonia was the most common presenting symptom, occurring in 75% of patients; muscle weakness was a presenting symptom in 59% of patients. The most frequent sign noted on physical examination was hypotonia (82%); respiratory distress, cardiomegaly, weakness, and cardiac failure were also frequent. Progression of disease was characterized by increased respiratory distress (72%), hypotonia (66%), and cardiac failure (58%). The most frequent supportive treatments were cardiac medications (52%) and oxygen supplementation (35%). Little psychosocial information was included. CONCLUSION: Physician narratives provide a unique perspective on the natural history of IOPD and are useful adjuncts to other data collection. Overall, there was concordance with the data obtained by the independent abstractors.
PURPOSE: To review the narratives that detailed the most important features of Infantile Onset Pompe disease (IOPD) from the physician's perspective, submitted as part of a large multicenter, multinational epidemiologic natural history study. METHODS: Inclusion in the epidemiologic study required documentation of onset of symptoms in the first 12 months of age and GAAenzyme deficiency or GAA mutation(s). In all, 300 cases were screened; 168 cases from 33 study sites in 9 countries met all eligibility criteria. In addition, 125 narratives that summarized the most important clinical features of IOPD, reflecting the opinion of the participating physicians who had provided access to the records for the independent review, were analyzed and are reported separately. A total of 98 variables were analyzed. RESULTS:Hypotonia was the most common presenting symptom, occurring in 75% of patients; muscle weakness was a presenting symptom in 59% of patients. The most frequent sign noted on physical examination was hypotonia (82%); respiratory distress, cardiomegaly, weakness, and cardiac failure were also frequent. Progression of disease was characterized by increased respiratory distress (72%), hypotonia (66%), and cardiac failure (58%). The most frequent supportive treatments were cardiac medications (52%) and oxygen supplementation (35%). Little psychosocial information was included. CONCLUSION: Physician narratives provide a unique perspective on the natural history of IOPD and are useful adjuncts to other data collection. Overall, there was concordance with the data obtained by the independent abstractors.
Authors: Mai K ElMallah; Silvia Pagliardini; Sara M Turner; Anthony J Cerreta; Darin J Falk; Barry J Byrne; John J Greer; David D Fuller Journal: Am J Respir Cell Mol Biol Date: 2015-09 Impact factor: 6.914
Authors: Daniel A Morris; Daniela Blaschke; Alice Krebs; Sima Canaan-Kühl; Ursula Plöckinger; Gesine Knobloch; Thula C Walter; York Kühnle; Leif-Hendrik Boldt; Elisabeth Kraigher-Krainer; Burkert Pieske; Wilhelm Haverkamp Journal: Int J Cardiovasc Imaging Date: 2015-03-06 Impact factor: 2.357
Authors: Allison M Keeler; Donghai Liu; Marina Zieger; Lang Xiong; Jeffrey Salemi; Karl Bellvé; Barry J Byrne; David D Fuller; Ronghua ZhuGe; Mai K ElMallah Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-03-23 Impact factor: 5.464
Authors: David D Fuller; Mai K ElMallah; Barbara K Smith; Manuela Corti; Lee Ann Lawson; Darin J Falk; Barry J Byrne Journal: Respir Physiol Neurobiol Date: 2013-06-21 Impact factor: 1.931
Authors: Paul T McIntosh; Lisa D Hobson-Webb; Zoheb B Kazi; Sean N Prater; Suhrad G Banugaria; Stephanie Austin; Raymond Wang; David S Enterline; Donald P Frush; Priya S Kishnani Journal: Mol Genet Metab Date: 2017-10-13 Impact factor: 4.797
Authors: Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson Journal: Genet Med Date: 2006-05 Impact factor: 8.822
Authors: Kun-Ze Lee; Kai Qiu; Milapjit S Sandhu; Mai K Elmallah; Darin J Falk; Michael A Lane; Paul J Reier; Barry J Byrne; David D Fuller Journal: Front Physiol Date: 2011-06-30 Impact factor: 4.566